Objective: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor.

This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic dermatitis (AD) in children aged 2 to 5 years. The PDUFA target action date of ...

Topical roflumilast, 0.05%, is under consideration for treating mild to moderate atopic dermatitis in children aged 2-5 years ...

Dexamethasone is a corticosteroid (steroid) that has many uses.

Specialty pharmacy expands access to an innovative, steroid-free treatment NEW PROVIDENCE, NJ, UNITED STATES, March 3, 2025 /EINPresswire / -- ...

The Californian company earlier announced the US Food and Drug Administration’s (FDA) acceptance of a supplemental New Drug ...

We demonstrated that phosphodiesterase 1A (PDE1A) promoted metastasis and EMT progression of NSCLC ... Vinpocetine (V107535) was purchased from Aladdin (Shanghai, China). SH-4-54 (S7337), SQ22536 ...

The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...

Palisade Bio (PALI) announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific ...

Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; driven by strong portfolio demand growth and ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The double-blind, randomized, placebo-controlled ...